Arthur Sackler

Arthur Sackler was a physician and pharmaceutical marketer whose methods helped make the modern drug industry’s promotional machinery more sophisticated and influential. The book presents him as a pioneer of doctor-focused advertising and of the effort to control the medical message surrounding a drug. Though he died in 1987, years before OxyContin was approved, his work supplies an important precedent for understanding how Purdue Frederick and its marketing arm, Purdue Pharma, later promoted opioids—and how claims about addiction risk could persist after their evidence had grown fragile.

Identity and Early Career

Arthur was one of three physician brothers—Mortimer, Raymond, and Arthur Sackler—who bought the small, family-owned Purdue Frederick in 1952. The company had only a few employees and annual sales of $20,000 when they acquired it. Before its entry into prescription pain relief, the business sold over-the-counter products including laxatives, earwax remover, and Betadine, an antiseptic also used to wash down the Apollo 11 spacecraft after its mission to the moon. The brothers later expanded internationally, acquiring Scottish and British drug companies.

Arthur’s career joined medical training to the commercial arts of publicity. He helped put himself and his two brothers through medical school by selling student newspaper advertisements and delivering flowers, sometimes with holes in his shoes. That early combination of resourcefulness and promotion foreshadowed his later role in pharmaceutical marketing: he did not treat advertising as an accessory to drug development, but as a way to organize how doctors encountered and understood a product.

Building a Medical Marketing System

The book characterizes Arthur as a transformative figure in American pharmaceutical promotion. During the 1960s, he pioneered the practice of showering doctors with favors and funding experts who would support drugmakers’ claims. He also launched a medical advertising agency and a medical newsmagazine before buying Purdue Frederick with his brothers. These ventures gave him means to influence not only the sales pitch but also the channels through which medical information circulated.

A central part of that influence was control over the company’s message. Under Arthur’s direction, preliminary scientific studies—studies the book describes as inevitably flawed—were used to bolster claims about the benefits of the drugs being promoted. His marketing prowess helped bring Valium and Librium to a broad audience, with the Rolling Stones’ nickname for the tranquilizers, Mother’s Little Helper, capturing their place in everyday life. The book’s larger concern is not simply that particular medicines became popular; it is that promotional authority and medical authority could reinforce one another, making a sales claim appear to carry the weight of science.

That concern becomes especially pointed in the history of addiction-risk claims. In 1996, a company training session for doctors described iatrogenic, or doctor-caused, addiction as exquisitely rare, while a claim of less than 1 percent addiction risk was also associated with an old letter. The book notes that Arthur’s brothers continued to excavate that flimsy, outdated letter nearly a decade after his death. More recent studies of people prescribed opioids for chronic nonmalignant pain put the addiction rate as high as 56 percent. The contrast illustrates how an early, weak claim could remain useful to a company long after the evidence around it had changed—and after the person whose marketing methods helped establish the company’s approach was gone.

Purdue, Pain Relief, and the Opioid Legacy

The brothers’ move into pain treatment began with MS Contin, an end-of-life painkiller derived from morphine, developed in 1984. Its name used an abbreviation of continuous, describing the drug’s delivery concept. By the mid-1990s, annual sales had reached $170 million, but the patent was approaching expiration. Purdue Frederick then launched OxyContin, a reformulation of oxycodone, intending to market it beyond hospice and end-of-life care. The Food and Drug Administration approved the drug in late 1995; Purdue Pharma managed its promotion and sales.

Arthur did not live to see OxyContin’s approval or its subsequent promotion. The chronology matters: the book does not place him in the later campaign as a living executive, but traces a continuity in methods. The company promoted the safety of its opioid-delivery system, and its representative, pain specialist J. David Haddox, told doctors that taking the medicine as prescribed carried an addiction risk of one-half of 1 percent. Read alongside Arthur’s earlier work—especially his investment in promotional channels and in scientific support for marketing claims—the OxyContin campaign appears within a longer history of managing what physicians were told about drug benefits and risks. The connection is institutional and methodological, not a claim that Arthur personally directed a campaign launched after his death.

Public Image, Secrecy, and Reputation

The Sackler brothers were famously private and, in public life, better known for philanthropy than for developing drugs. Their circle included British royalty, Nobel Prize winners, and executives associated with art wings bearing the Sackler name, from the Smithsonian to the Metropolitan Museum of Art. Arthur was especially devoted to collecting. He persuaded the Metropolitan Museum of Art to let him reimburse it for four major works it already owned so that they could be displayed with his name as donor. At his death in 1987, he was celebrated for entrepreneurial vision and an apparently boundless appetite for collecting.

That public stature did not mean he had been fully accepted by the Upper East Side society to which he aspired. At his memorial service in the Temple of Dendur, inside the Metropolitan Museum of Art’s Sackler Wing, New York mayor Ed Koch remarked, “I don’t know why, but Jews aren’t buried in synagogues. Well, Arthur built his own temple.” The setting joined Arthur’s ambition, philanthropy, and art collecting in a single image: the institution that displayed his name also became the place of his memorial.

The same public legacy sat uneasily beside his aversion to uncontrolled publicity. A Vanity Fair writer observed shortly after Arthur’s death that he hated bad press and any press he did not direct himself. The book links this insistence on secrecy to his devotion to money and art, and imagines that he would have abhorred everything about the Abingdon hearing. In that contrast, Arthur’s defining achievement and vulnerability converge: he helped build a system for shaping what doctors heard about medicines, yet his later reputation could not be confined to the message its architects preferred. His significance in the book is therefore both personal and structural—a gifted marketer whose techniques outlived him and became part of the history through which Purdue’s opioid promotion must be understood.